Sanofi says rare lung disease drug outperforms standard care in trial
- Posted on May 18, 2026
- By Bing News
- 0 Views
- 1 min read
Sanofi says rare lung disease drug outperforms standard care in trial
By Bhanvi Satija LONDON, May 18 (Reuters) - French drugmaker Sanofi said on Monday a trial showed its rare disease therapy was better than standard care in raising levels of a key protein in patients with a genetic form of lung disease. The data in the head-to-head study offers a potential boost to Sanofi's $2.2 billion bet on efdoralprin alfa, the experimental therapy it acquired through its
)
